Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6335 |
Tie2 kinase inhibitor 1
Tie2 kinase inhibitor |
Tie-2 | Tyrosine Kinase/Adaptors |
Tie2 kinase inhibitor 1 (Tie2 kinase inhibitor) 是Tie2激酶选择性抑制剂9IC50:250 nM),具有抗癌作用。 | |||
T6154 |
SU11274
Met Kinase Inhibitor,PKI-SU11274 |
Apoptosis; VEGFR; FGFR; c-Met/HGFR; CDK; Autophagy | Angiogenesis; Apoptosis; Autophagy; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors |
SU11274 (Met Kinase Inhibitor) 是一种选择性的 Met 抑制剂,IC50值为 10 nM。它对 PGDFRβ,EGFR 或 Tie2 没有抑制作用。 | |||
T22259 |
AMG-Tie2-1
AMG-Tie2,4-甲基-3-[[3-[2-(甲基氨基)-4-嘧啶基]-2-吡啶基]氧基]-N-[3-(三氟甲基)苯基]苯甲酰胺 |
Others | Others |
AMG-Tie2-1 is a dual inhibitor of VEGF receptor 2 (VEGFR2) and tunica interna endothelial cell kinase 2 (Tie2). | |||
T36718 |
Tie2 Inhibitor 7
|
||
Tie2 Inhibitor 7 blocks Tie2 kinase activity with a Ki value of 1.3 μM.. It has been shown to inhibit angiopoietin 1-induced Tie2 autophosphorylation and downstream signaling with an IC50 value of 0.3 μM. This compound can prevent endothelial cell tube formation and aberrant vessel growth in a rat model of Matrigel-induced choroidal neovascularization. | |||
T68286 |
CE-245677 mesylate
|
||
CE-245677 is a selective, orally active Tie2 kinase inhibitor identified by Pfizer previously in development for the treatment of certain cancers. CE-245,677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases with a cellular IC50 of 4.7 and 1 nM, resp., displays >100x selectivity against a number of other angiogenic receptor tyrosine kinases (e.g. KDR, PDGFR, FGFR) and gene family panels, and demonstrates good oral absorption in in vivo rat PK studies (F=80%). | |||
T68539 |
CEP-11981
BOL 303213X,ESK981 ; BOL 303213X,ESK981 |
||
CEP-11981 (ESK981 ; BOL 303213X) 是一种具有口服活性的酪氨酸激酶抑制剂(TKI),可以靶向 TIE2,VEGFR1-3和FGFR1,具有潜在的抗肿瘤和抗血管生成效果。 |